Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lactitol

FDA-approved product (for solution, oral), marketed as Pizensy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lactitol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Constipation disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Osmotically acting laxatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lactitol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lactitol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lactitol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CINC424A2X01B Rollover Protocol

    NCT02386800 · start 2015-03-05

    Registered record
    Registry ID
    NCT02386800
    Conditions
    Primary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease; Acute Myeloid Leukemia; Thalassemia
    Interventions
    ruxolitinib; panobinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2015-03-05
    Completion
    2032-04-05
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease; Acute Myeloid Leukemia +1 more
    Interventionruxolitinib; panobinostat
    PhasePhase 4
    Registry statusActive not recruiting

  • Oxytocin and Learning for Teaching

    NCT02393443 · start 2015-01

    Registered record
    Registry ID
    NCT02393443
    Conditions
    Social Psychology
    Interventions
    Intranasal oxytocin; Intranasal placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-07
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Psychology
    InterventionIntranasal oxytocin; Intranasal placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients

    NCT02293668 · start 2014-11

    Registered record
    Registry ID
    NCT02293668
    Conditions
    Infertility
    Interventions
    FSH 225IU and hMG 225IU; FSH 150IU and hMG 150IU; Letrozole 5mg and hMG 150IU
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-11
    Completion
    2015-08
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionFSH 225IU and hMG 225IU; FSH 150IU and hMG 150IU; Letrozole 5mg and hMG 150IU
    PhaseNot applicable
    Registry statusCompleted

  • Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

    NCT02257385 · start 2014-10-15

    Registered record
    Registry ID
    NCT02257385
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    UMEC/VI; UMEC/VI matching placebo; Tiotropium; Tiotropium matching placebo; Indacaterol; Indacaterol matching placebo; Albuterol/salbutamol Metered Dose Inhaler (MDI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-15
    Completion
    2015-05-04
    Enrolment
    967

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionUMEC/VI; UMEC/VI matching placebo; Tiotropium; Tiotropium matching placebo +3 more
    PhasePhase 3
    Registry statusCompleted

  • Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study

    NCT01853787 · start 2014-07

    Registered record
    Registry ID
    NCT01853787
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    Formoterol Fumarate; Salmeterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2015-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionFormoterol Fumarate; Salmeterol
    PhasePhase 4
    Registry statusCompleted

  • Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

    NCT01972750 · start 2013-10

    Registered record
    Registry ID
    NCT01972750
    Conditions
    First or Second Recurrence of Glioblastoma
    Interventions
    Dovitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2016-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFirst or Second Recurrence of Glioblastoma
    InterventionDovitinib
    PhasePhase 1
    Registry statusUnknown

  • Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy

    NCT02022137 · start 2013-10

    Registered record
    Registry ID
    NCT02022137
    Conditions
    Liver Cirrhosis
    Interventions
    Red cereal bar; Green cereal bar; White cereal bar
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-10
    Completion
    2016-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    InterventionRed cereal bar; Green cereal bar; White cereal bar
    PhaseNot applicable
    Registry statusCompleted

  • Adherence to Antimalarial Drugs in Sierra Leone

    NCT01967472 · start 2013-09-16

    Registered record
    Registry ID
    NCT01967472
    Conditions
    Malaria
    Interventions
    amodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09-16
    Completion
    2014-01
    Enrolment
    1,145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionamodiaquine-artesunate (AQAS) fixed-dose; Artemether-lumefantrine combination (AL) dispersable
    PhaseNot applicable
    Registry statusCompleted

  • H7N9 Mix and Match With MF59 in Healthy Adults

    NCT01938742 · start 2013-09

    Registered record
    Registry ID
    NCT01938742
    Conditions
    Influenza
    Interventions
    Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; MF59
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-11
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza
    InterventionInfluenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; MF59
    PhasePhase 2
    Registry statusCompleted

  • A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

    NCT01911221 · start 2013-08

    Registered record
    Registry ID
    NCT01911221
    Conditions
    Prevention of the Meningococcal Disease
    Interventions
    rMenB+OMV NZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-04
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention of the Meningococcal Disease
    InterventionrMenB+OMV NZ
    PhasePhase 3
    Registry statusCompleted

  • QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

    NCT01782326 · start 2013-07

    Registered record
    Registry ID
    NCT01782326
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07
    Completion
    2015-09
    Enrolment
    3,362

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionQVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
    PhasePhase 3
    Registry statusCompleted

  • Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

    NCT01735955 · start 2013-03-29

    Registered record
    Registry ID
    NCT01735955
    Conditions
    Chronic Myelogenous Leukemia (CML); Metastatic Gastrointestinal Stromal Tumors (GIST); Acute Lymphoblastic Leukemia (ALL); Receptor Tyrosine Kinase (KIT) Mutated Melanoma
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-03-29
    Completion
    2023-07-07
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia (CML); Metastatic Gastrointestinal Stromal Tumors (GIST); Acute Lymphoblastic Leukemia (ALL); Receptor Tyrosine Kinase (KIT) Mutated Melanoma
    InterventionNilotinib
    PhasePhase 4
    Registry statusCompleted

  • The Effects of Atorvastatin Treatment in COPD Patients

    NCT01748279 · start 2012-12

    Registered record
    Registry ID
    NCT01748279
    Conditions
    COPD
    Interventions
    Atorvastatin; Formoterol; Lactose tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionAtorvastatin; Formoterol; Lactose tablet
    PhasePhase 4
    Registry statusCompleted

  • A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

    NCT01709903 · start 2012-11

    Registered record
    Registry ID
    NCT01709903
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    QVA149; Fluticasone/salmeterol; Placebo to QVA149; Placebo to fluticasone/salmeterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-02
    Enrolment
    744

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionQVA149; Fluticasone/salmeterol; Placebo to QVA149; Placebo to fluticasone/salmeterol
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

    NCT01311505 · start 2011-04

    Registered record
    Registry ID
    NCT01311505
    Conditions
    Tuberculosis
    Interventions
    Myrin© 2 (Rifampicin + Isoniazid); Rimactane® (Rifampicin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionMyrin© 2 (Rifampicin + Isoniazid); Rimactane® (Rifampicin)
    PhasePhase 1
    Registry statusCompleted